These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 15090960)

  • 21. sGC stimulation totally reverses hypoxia-induced pulmonary vasoconstriction alone and combined with dual endothelin-receptor blockade in a porcine model.
    Lundgren J; Kylhammar D; Hedelin P; Rådegran G
    Acta Physiol (Oxf); 2012 Nov; 206(3):178-94. PubMed ID: 22682645
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cardiopulmonary bypass is associated with altered vascular reactivity of isolated pulmonary artery in a porcine model: therapeutic potential of inhaled tezosentan.
    Mommerot A; Denault AY; Dupuis J; Carrier M; Perrault LP
    J Cardiothorac Vasc Anesth; 2014 Jun; 28(3):698-708. PubMed ID: 24917060
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hemodynamic and clinical effects of tezosentan, an intravenous dual endothelin receptor antagonist, in patients hospitalized for acute decompensated heart failure.
    Torre-Amione G; Young JB; Colucci WS; Lewis BS; Pratt C; Cotter G; Stangl K; Elkayam U; Teerlink JR; Frey A; Rainisio M; Kobrin I
    J Am Coll Cardiol; 2003 Jul; 42(1):140-7. PubMed ID: 12849674
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Haemodynamic and neuroendocrine effects of tezosentan in chronic experimental pulmonary hypertension.
    Lourenço AP; Vasques-Nóvoa F; Oliveira-Pinto J; Fontoura D; Roncon-Albuquerque R; Leite-Moreira AF
    Intensive Care Med; 2012 Jun; 38(6):1050-60. PubMed ID: 22349420
    [TBL] [Abstract][Full Text] [Related]  

  • 25. RITZ-5: randomized intravenous TeZosentan (an endothelin-A/B antagonist) for the treatment of pulmonary edema: a prospective, multicenter, double-blind, placebo-controlled study.
    Kaluski E; Kobrin I; Zimlichman R; Marmor A; Krakov O; Milo O; Frey A; Kaplan S; Krakover R; Caspi A; Vered Z; Cotter G
    J Am Coll Cardiol; 2003 Jan; 41(2):204-10. PubMed ID: 12535809
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Inhaled nitric oxide reduces lung edema during fluid resuscitation in ovine acute lung injury.
    Stubbe HD; Westphal M; Van Aken H; Hucklenbruch C; Lauer S; Jahn UR; Hinder F
    Intensive Care Med; 2003 Oct; 29(10):1790-7. PubMed ID: 12768236
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Intravenous tezosentan improves gas exchange and hemodynamics in acute lung injury secondary to meconium aspiration.
    Geiger R; Kleinsasser A; Meier S; Neu N; Pajk W; Fischer V; Treml B; Stein JI; Loeckinger A
    Intensive Care Med; 2008 Feb; 34(2):368-76. PubMed ID: 17898997
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Hemodynamics and pharmacokinetics of tezosentan, a dual endothelin receptor antagonist, in patients with cirrhosis.
    Lebrec D; Bosch J; Jalan R; Dudley FJ; Jessic R; Moreau R; Garcia-Pagan JC; Mookerjee RP; Chiossi E; Van Giersbergen PL; Kusic-Pajic A; Dingemanse J
    Eur J Clin Pharmacol; 2012 May; 68(5):533-41. PubMed ID: 22101624
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dual endothelin receptor blockade with tezosentan markedly attenuates hypoxia-induced pulmonary vasoconstriction in a porcine model.
    Hedelin P; Kylhammar D; Rådegran G
    Acta Physiol (Oxf); 2012 Mar; 204(3):419-34. PubMed ID: 21726419
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacokinetics and pharmacodynamics of tezosentan, an intravenous dual endothelin receptor antagonist, following chronic infusion in healthy subjects.
    Dingemanse J; Clozel M; van Giersbergen PL
    Br J Clin Pharmacol; 2002 Apr; 53(4):355-62. PubMed ID: 11966665
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Endothelin antagonists: new bullets against lung injury?
    Leeman M
    Crit Care; 2005 Jun; 9(3):245-6. PubMed ID: 15987411
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The endothelin receptor antagonist tezosentan improves renal microcirculation in a porcine model of endotoxemic shock.
    Fenhammar J; Andersson A; Frithiof R; Forestier J; Weitzberg E; Sollevi A; Hjelmqvist H
    Acta Anaesthesiol Scand; 2008 Nov; 52(10):1385-93. PubMed ID: 19025532
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of a dual endothelin-1 receptor antagonist on airway obstruction and acute lung injury in sheep following smoke inhalation and burn injury.
    Cox RA; Enkhabaatar P; Burke AS; Katahira J; Shimoda K; Chandra A; Traber LD; Herndon DN; Hawkins HK; Traber DL
    Clin Sci (Lond); 2005 Mar; 108(3):265-72. PubMed ID: 15554871
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Endothelin receptor antagonism by tezosentan attenuates lung injury induced by aortic ischemia-reperfusion.
    Kiriş I; Narin C; Gülmen S; Yilmaz N; Sütçü R; Kapucuoğlu N
    Ann Vasc Surg; 2009; 23(3):382-91. PubMed ID: 19135850
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Endothelin receptor antagonist improves donor lung function in an ex vivo perfusion system.
    Walweel K; Skeggs K; Boon AC; See Hoe LE; Bouquet M; Obonyo NG; Pedersen SE; Diab SD; Passmore MR; Hyslop K; Wood ES; Reid J; Colombo SM; Bartnikowski NJ; Wells MA; Black D; Pimenta LP; Stevenson AK; Bisht K; Marshall L; Prabhu DA; James L; Platts DG; Macdonald PS; McGiffin DC; Suen JY; Fraser JF
    J Biomed Sci; 2020 Oct; 27(1):96. PubMed ID: 33008372
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tezosentan, an endothelin receptor antagonist, limits liver injury in endotoxin challenged cirrhotic rats.
    Urbanowicz W; Sogni P; Moreau R; Tazi KA; Barriere E; Poirel O; Martin A; Guimont MC; Cazals-Hatem D; Lebrec D
    Gut; 2004 Dec; 53(12):1844-9. PubMed ID: 15542526
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Endothelin receptor blockade with tezosentan ameliorates myocardial injury induced by abdominal aortic ischemia-reperfusion.
    Narin C; Kiris I; Gülmen S; Toy H; Yilmaz N; Sütcü R
    Tohoku J Exp Med; 2008 Nov; 216(3):267-76. PubMed ID: 18987461
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Tezosentan decreases pulmonary artery pressure and improves survival rate in an animal model of meconium aspiration.
    Geiger R; Pajk W; Neu N; Maier S; Kleinsasser A; Fratz S; Navarro-Psiha S; Fischer V; Treml B; Loeckinger A
    Pediatr Res; 2006 Jan; 59(1):147-50. PubMed ID: 16327003
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of tezosentan, a dual endothelin receptor antagonist, on the cardiovascular and renal systems of neonatal piglets.
    Chin A; Radhakrishnan J; Fornell L; John E
    J Pediatr Surg; 2001 Dec; 36(12):1824-8. PubMed ID: 11733915
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Myocardial protective effect of tezosentan, an endothelin receptor antagonist, for ischemia-reperfusion injury in experimental heart failure models.
    Ryu SM; Kim HJ; Cho KR; Jo WM
    J Korean Med Sci; 2009 Oct; 24(5):782-8. PubMed ID: 19794971
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.